Xanthomicrol

Xanthomicrol is a polymethoxylated flavonoid found primarily in Satureja species and Calamintha incana that exerts anticancer effects by inhibiting angiogenesis, inducing apoptosis, and arresting cell cycle progression at the G2/M checkpoint. Its primary mechanisms involve suppression of VEGF-driven neovascularization and activation of caspase-dependent cell death pathways in malignant cell lines.

Origin & History

Xanthomicrol is a flavonoid, specifically a flavone, primarily extracted from the medicinal plant Dracocephalum kotschyi. It has been chemically synthesized with a purity of over 98% for research purposes.

Historical & Cultural Context

There are no detailed accounts of traditional or historical uses of xanthomicrol specifically. It is recognized as a natural component of Dracocephalum kotschyi, a medicinal herb.

Health Benefits

• Inhibits angiogenesis and tumor growth in vivo, showing antiangiogenic effects comparable to thalidomide [1]. • Induces apoptosis and G2/M cell cycle arrest in HCT116 colon cancer cells [2]. • Demonstrates cytotoxicity in HeLa cells while being selective over normal fibroblasts [3]. • Suppresses proliferation and invasion in triple-negative breast cancer models [7]. • Reduces migration in hepatocellular carcinoma cells [9].

How It Works

Xanthomicrol suppresses angiogenesis by inhibiting VEGF receptor signaling, reducing endothelial cell proliferation and tube formation comparably to thalidomide in vivo models. In HCT116 colon cancer cells, it activates the intrinsic apoptotic pathway through caspase-3 and caspase-9 cleavage while simultaneously inducing G2/M cell cycle arrest, likely via downregulation of cyclin B1 and CDK1 activity. Its selective cytotoxicity in HeLa cervical cancer cells over normal fibroblasts suggests partial targeting of cancer-specific survival pathways, potentially involving suppression of NF-κB or PI3K/Akt signaling.

Scientific Research

The research on xanthomicrol is currently limited to preclinical in vitro and in vivo animal studies; no human clinical trials or meta-analyses are available. Key studies include its effects on mouse melanoma models and various cancer cell lines.

Clinical Summary

Research on xanthomicrol remains entirely preclinical, with no published human clinical trials as of 2024. In vitro studies using HCT116 colon cancer and HeLa cervical cancer cell lines have demonstrated dose-dependent cytotoxicity and apoptosis induction, though specific IC50 values vary by model. In vivo murine models of angiogenesis showed antiangiogenic effects comparable to thalidomide, a clinically used reference compound, lending biological plausibility to the findings. The overall evidence base is preliminary; efficacy and safety in humans have not been established, and extrapolation from cell and animal studies should be made with caution.

Nutritional Profile

Xanthomicrol (5,4'-dihydroxy-6,7,8-trimethoxyflavone; C₁₈H₁₆O₇; MW ~344.32 g/mol) is a polymethoxylated flavone, not a nutritional macronutrient source. It is a specialized bioactive secondary metabolite found in select Lamiaceae species. Key details: • Primary natural sources: Aerial parts of Dracocephalum kotschyi (Iranian dragonhead), Orthodon dianthera, and certain Salvia species. Concentrations in dried plant material are typically low, estimated in the range of 0.01–0.5% w/w depending on plant part, chemotype, and extraction method. • Chemical class: Polymethoxylated flavone with three methoxy groups at C-6, C-7, and C-8, and hydroxyl groups at C-5 and C-4'. This high degree of methoxylation increases lipophilicity (estimated LogP ~2.5–3.0) relative to unmethylated flavones, which may enhance passive intestinal absorption and metabolic stability compared to polyhydroxylated analogs. • Bioavailability notes: No dedicated human pharmacokinetic studies are available. Based on structural analogy to other polymethoxylated flavones (e.g., nobiletin, tangeretin), oral bioavailability is expected to be modest but improved over hydroxylated flavones due to resistance to Phase II conjugation (glucuronidation/sulfation). Lipophilic formulation or co-administration with dietary fats may enhance absorption. Hepatic CYP450-mediated O-demethylation is a likely primary metabolic route, potentially generating active hydroxylated metabolites. • It provides negligible calories, protein, fat, carbohydrate, fiber, vitamins, or minerals at pharmacologically relevant doses (typically studied in vitro at 5–100 µM; in vivo rodent studies use doses in the range of 25–200 mg/kg). • Co-occurring bioactives in source plants: Dracocephalum kotschyi extracts also contain calycopterin, cirsimaritin, isokaempferide, luteolin, and rosmarinic acid, which may contribute to synergistic biological effects observed with crude extracts versus isolated xanthomicrol. • No established Dietary Reference Intake (DRI), Recommended Daily Allowance (RDA), or tolerable upper intake level exists for xanthomicrol. It is classified as a phytochemical research compound rather than a nutrient.

Preparation & Dosage

Preclinical studies used an intraperitoneal dosage of 50 mg/kg daily in mice for 21 days. In vitro studies applied concentrations ranging from 15-200 μM, depending on the cell line. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Resveratrol, Quercetin, EGCG, Sulforaphane

Safety & Interactions

No human safety data, toxicology studies, or established safe dosage ranges exist for xanthomicrol supplementation. Given its potent pro-apoptotic and antiangiogenic activity demonstrated in cell models, theoretical interactions with anticoagulants, chemotherapy agents, or antiangiogenic drugs such as bevacizumab cannot be excluded. Pregnant or breastfeeding individuals should avoid xanthomicrol-containing supplements entirely due to the complete absence of reproductive safety data and the theoretical risk posed by antiangiogenic compounds to fetal vascularization. Individuals on cancer treatment protocols should consult an oncologist before use.